Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
about
Lupus nephritis: the evolving role of novel therapeuticsUnmet medical needs in systemic lupus erythematosusThe pathogenesis, diagnosis and treatment of lupus nephritis.Current status of lupus nephritis.Renal involvement in autoimmune connective tissue diseases.In-/off-label use of biologic therapy in systemic lupus erythematosus.Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineEfficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapyLatest advances in connective tissue disorders.B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.Experience with low-dose rituximab in off-label indications at two tertiary hospitals.Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.The multifaceted aspects of refractory lupus nephritis.Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.Current role of rituximab in systemic lupus erythematosus.Lupus nephritis management guidelines compared.Mycophenolate mofetil for lupus nephritis: an update.Why are kids with lupus at an increased risk of cardiovascular disease?Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.Towards new avenues in the management of lupus glomerulonephritis.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management.Treatment Algorithms in Systemic Lupus Erythematosus.[Established medications : new areas of application].Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab.Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives.Single-dose rituximab in refractory lupus nephritis.The pathogenesis of lupus nephritis.
P2860
Q26998390-BB2D9BBC-724F-484F-B108-E7EEBB41C133Q27005906-31E36BB3-98EF-4115-962D-3760444AB810Q30596968-68EF30D6-410C-44DC-8826-7BED1868A107Q33882751-DC2A9FC3-F9DE-4F9B-91C9-0EF2DA88393BQ34654954-169D6D85-891E-4F0C-BA42-1F0F1C442530Q35094536-B63A5AE9-AC8B-4221-9917-52B53F6921F7Q36088877-4FC7BAE0-CCAA-4581-A40C-08DB4115DF1AQ36518986-D558D6C2-4B67-426D-8C36-0ABBB2907CBAQ37058776-7B452673-CF79-4A34-A127-B0D87AE793B6Q38086135-FEB7A230-5960-40A8-B6E9-B6BC0138651FQ38126924-311A6F24-C57F-46D2-A057-8FFAAE34784BQ38153509-D6B8FB57-D0B1-4074-982F-4A090FA21370Q38192656-727658CF-0118-4ED7-88D0-5BF931460D8DQ38192683-77DFFF15-C590-455A-A324-6DCBC1D1A2C7Q38285375-08E26DAF-0C89-48EA-A60E-D723E212BF9DQ38286372-4ACC8881-BC6A-4981-81F2-4E3A26BFCAB6Q38293284-E797B12C-092D-475D-96D9-5FEDEF666B1EQ38446941-B4D7E3B2-A5A5-4B2A-971D-52048EB460E0Q38585887-8659375A-DCCE-4AB7-9597-5CDC3B04F721Q38591752-96218BDA-3D4B-446C-B94E-0A898041806CQ38638596-D7F6F895-82C0-491C-80B0-5D40A2BE6826Q38686467-83C36546-B915-492E-A871-D3F90E92CC20Q38690844-0555760F-A1F5-41F7-BD20-6A0E5397431EQ39218839-48B7A0E1-CB56-4CF9-A641-A3CD6A50A919Q39570030-1C3A215E-D823-45EF-B0EE-1248846C1155Q41207949-7849F4A8-2485-4098-9987-42F8F2741FE5Q44480906-CE2346F0-87BA-42E6-B3EF-B06D0629975AQ45871306-69EF014D-BB69-4782-8732-3FFB0FC67C7FQ50116281-7EC81D6F-62A1-49E4-B190-396573B450F0Q51067608-D7F0A7E2-49E6-4AE5-83EC-98FF3CB31599Q51140299-EDBE771F-809A-4449-91AD-22A20A403F44Q51201612-E0E4DBB3-E53F-457A-B00E-3DEA253F291DQ51345238-BADEC970-560B-4DD6-A84B-C1EAB699D49CQ51729156-B83F9C15-B205-43AD-9E25-9A3B6449D422Q51868414-9FD4C3A4-2172-4777-9E0B-56C8669F3FCA
P2860
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
@en
type
label
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
@en
prefLabel
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
@en
P2093
P2860
P356
P1476
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
@en
P2093
Angelika Schröttle
Christoph Römmele
Marc Weidenbusch
P2860
P304
P356
10.1093/NDT/GFS285
P407
P577
2012-07-03T00:00:00Z